carbamazepine has been researched along with alpha-Galactosidase A Deficiency in 12 studies
Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.
carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 22-year-old male with Fabry disease presented with proteinuria during ERT with agalsidase-β and carbamazepine." | 8.12 | Membranous nephropathy without vacuolated podocytes in Fabry disease treated with agalsidase-β and carbamazepine: A case report. ( Aoyagi, J; Ito, T; Kanai, T; Yamagata, T, 2022) |
| "A 22-year-old male with Fabry disease presented with proteinuria during ERT with agalsidase-β and carbamazepine." | 4.12 | Membranous nephropathy without vacuolated podocytes in Fabry disease treated with agalsidase-β and carbamazepine: A case report. ( Aoyagi, J; Ito, T; Kanai, T; Yamagata, T, 2022) |
| "Seven patients with Fabry's disease and severe pain received carbamazepine (CMZ)." | 3.67 | Carbamazepine in Fabry's disease: effective analgesia with dose-dependent exacerbation of autonomic dysfunction. ( Barton, NW; Filling-Katz, MR; Fink, JK; Merrick, HF; Miles, RB; Sokol, J, 1989) |
| "Neuropathic pain is one of the key features of (classical) Fabry disease (FD)." | 2.53 | Pain management strategies for neuropathic pain in Fabry disease--a systematic review. ( Biegstraaten, M; Hollak, CE; Linthorst, GE; Schuller, Y; Van Schaik, IN, 2016) |
| "Fabry's disease is an X-linked multisistemic lisosomal storage disorder caused by deficiency or absence in α-Galatosidase A." | 1.48 | [Neuropathy and Fabry's disease. Report of five cases]. ( Jara, P; Matamala, JM; Verdugo, R, 2018) |
| "Six patients (18%) developed psychiatric disorders." | 1.29 | Psychiatric disorders in patients with Fabry's disease. ( Grewal, RP, 1993) |
| "Fabry's disease was confirmed by discovering typical corneal lesion, a low leucocyte (W." | 1.26 | [Fabry's disease. Carbamazepine therapy in acrodyniform syndrome]. ( Dufier, JL; Gubler, MC; Guivarch, M; Lenoir, G; Rivron, M; Tome, FS, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (41.67) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 2 (16.67) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J | 1 |
| Bai, L | 1 |
| He, Y | 1 |
| Kanai, T | 1 |
| Ito, T | 1 |
| Aoyagi, J | 1 |
| Yamagata, T | 1 |
| Jara, P | 1 |
| Matamala, JM | 1 |
| Verdugo, R | 1 |
| Schuller, Y | 1 |
| Linthorst, GE | 1 |
| Hollak, CE | 1 |
| Van Schaik, IN | 1 |
| Biegstraaten, M | 1 |
| Eto, Y | 1 |
| Grewal, RP | 1 |
| Okumiya, T | 1 |
| Sakuraba, H | 2 |
| Lenoir, G | 1 |
| Rivron, M | 1 |
| Gubler, MC | 1 |
| Dufier, JL | 1 |
| Tome, FS | 1 |
| Guivarch, M | 1 |
| Atzpodien, W | 2 |
| Kremer, GJ | 2 |
| Schnellbacher, E | 1 |
| Denk, R | 1 |
| Haferkamp, G | 1 |
| Bierbach, H | 1 |
| Filling-Katz, MR | 1 |
| Merrick, HF | 1 |
| Fink, JK | 1 |
| Miles, RB | 1 |
| Sokol, J | 1 |
| Barton, NW | 1 |
| Igarashi, T | 1 |
| Suzuki, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Lipidomics and Functional Analyses of Platelets in Fabry Disease[NCT02649660] | 32 participants (Anticipated) | Observational | 2015-10-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for carbamazepine and alpha-Galactosidase A Deficiency
| Article | Year |
|---|---|
Pain management strategies for neuropathic pain in Fabry disease--a systematic review.
Topics: Amines; Anticonvulsants; Carbamazepine; Cyclohexanecarboxylic Acids; Fabry Disease; Gabapentin; gamm | 2016 |
[Lisosomal disease with endocrine abnormality].
Topics: alpha-Galactosidase; Carbamazepine; Diuretics; Endocrine System Diseases; Fabry Disease; Humans; Iso | 2006 |
[Fabry disease (alpha-galactosidase deficiency)].
Topics: alpha-Galactosidase; Analgesics, Non-Narcotic; Carbamazepine; Fabry Disease; Humans; Lysosomes; Muta | 1995 |
9 other studies available for carbamazepine and alpha-Galactosidase A Deficiency
| Article | Year |
|---|---|
A possible case of carbamazepine-induced renal phospholipidosis mimicking Fabry disease.
Topics: alpha-Galactosidase; Carbamazepine; Fabry Disease; Humans; Kidney; Kidney Diseases; Male; Proteinuri | 2022 |
Membranous nephropathy without vacuolated podocytes in Fabry disease treated with agalsidase-β and carbamazepine: A case report.
Topics: Adult; Carbamazepine; Enzyme Replacement Therapy; Fabry Disease; Glomerulonephritis, Membranous; Hum | 2022 |
[Neuropathy and Fabry's disease. Report of five cases].
Topics: Adult; Analgesics, Non-Narcotic; Carbamazepine; Enzyme Replacement Therapy; Fabry Disease; Female; H | 2018 |
Psychiatric disorders in patients with Fabry's disease.
Topics: Adult; alpha-Galactosidase; Carbamazepine; Cerebrovascular Disorders; Diplopia; Fabry Disease; Human | 1993 |
[Fabry's disease. Carbamazepine therapy in acrodyniform syndrome].
Topics: Adult; Carbamazepine; Corneal Diseases; Fabry Disease; Humans; Kidney Glomerulus; Leukocyte Count; M | 1977 |
[Angiokeratoma corporis diffusum (Fabry's disease). Biochemical diagnosis in plasma].
Topics: Adult; Carbamazepine; Electrocardiography; Fabry Disease; Galactosidases; Glycolipids; Heterozygote; | 1975 |
[Fabry's diffuse angiokeratoma corporis].
Topics: Age Factors; Carbamazepine; Fabry Disease; Galactosidases; Glycolipids; Heterozygote; Humans; Kidney | 1975 |
Carbamazepine in Fabry's disease: effective analgesia with dose-dependent exacerbation of autonomic dysfunction.
Topics: Adult; Analgesia; Autonomic Nervous System; Carbamazepine; Child, Preschool; Fabry Disease; Humans; | 1989 |
Activation of platelet function in Fabry's disease.
Topics: Adolescent; Adult; alpha-Galactosidase; Carbamazepine; Child; Fabry Disease; Female; Heterozygote; H | 1986 |